Showing 2171-2180 of 5909 results for "".
- Telemedicine Useful in Detecting Retinopathy of Prematurityhttps://modernod.com/news/telemedicine-useful-in-detecting-retinopathy-of-prematurity/2480230/Telemedicine has similar accuracy to ophthalmoscopy in detecting clinically significant retinopathy of prematurity (ROP), researchers say, according to a report in Reuters Health. “ROP is a leading cause of childhood blindness in the U.S. and throughout the world, yet it is often dif
- GlobalData: AI-Based Diabetic Retinopathy Device Can Reduce Burden on US Healthcare Systemhttps://modernod.com/news/globaldata-ai-based-diabetic-retinopathy-device-can-reduce-burden-on-us-healthcare-system/2480234/Iowa-based artificial intelligence (AI) diagnostics company IDx recently received market approval from the FDA for its AI-based medical device, IDx-DR, to detect greater than a mild level of diabetic retinopathy in adults. As the first of its kind to be authorized for commercialization, IDx-DR ha
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.
- Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Researchhttps://modernod.com/news/verana-health-partners-with-foundation-fighting-blindness-to-integrate-genetic-testing-data-into-real-world-evidence-research/2481940/Verana Health and the Foundation Fighting Blindness announced a partnership focused on providing the life sciences community with deeper and broader data to optimize and expedite clinical trials. Under the partnership, the Foundation will provide Verana with de-identified genomics
- Bausch + Lomb to Acquire Xiidra from Novartishttps://modernod.com/news/bausch-lomb-will-acquire-xiidra/2481704/Bausch + Lomb announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5%. Xiidra is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DE
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- Rayner Establishes Direct Presence in Francehttps://modernod.com/news/rayner-establishes-direct-presence-in-france/2480956/Rayner announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of ophthalmic specialist area managers focussed on delivering service and support. Through this team, French ophthalmologist
- Outlook Therapeutics Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-phase-3-norse-two-trial-of-lytenava-for-wet-amd/2479428/Outlook Therapeutics announced positive clinical and highly statistically significant topline results from its pivotal phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010/Lytenava (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). “We are de